http://purl.org/np/RAEYDBJplKT7agOpTcNYIHtwVLOaY__E2niBhZUqcU9mM#Head http://purl.org/np/RAEYDBJplKT7agOpTcNYIHtwVLOaY__E2niBhZUqcU9mM http://www.nanopub.org/nschema#hasAssertion http://purl.org/np/RAEYDBJplKT7agOpTcNYIHtwVLOaY__E2niBhZUqcU9mM#assertion http://purl.org/np/RAEYDBJplKT7agOpTcNYIHtwVLOaY__E2niBhZUqcU9mM http://www.nanopub.org/nschema#hasProvenance http://purl.org/np/RAEYDBJplKT7agOpTcNYIHtwVLOaY__E2niBhZUqcU9mM#provenance http://purl.org/np/RAEYDBJplKT7agOpTcNYIHtwVLOaY__E2niBhZUqcU9mM http://www.nanopub.org/nschema#hasPublicationInfo http://purl.org/np/RAEYDBJplKT7agOpTcNYIHtwVLOaY__E2niBhZUqcU9mM#pubinfo http://purl.org/np/RAEYDBJplKT7agOpTcNYIHtwVLOaY__E2niBhZUqcU9mM http://www.w3.org/1999/02/22-rdf-syntax-ns#type http://www.nanopub.org/nschema#Nanopublication http://purl.org/np/RAEYDBJplKT7agOpTcNYIHtwVLOaY__E2niBhZUqcU9mM#assertion http://purl.obolibrary.org/obo/DOID_9352 https://w3id.org/biolink/vocab/category https://w3id.org/biolink/vocab/Disease http://purl.org/np/RAEYDBJplKT7agOpTcNYIHtwVLOaY__E2niBhZUqcU9mM#association http://www.w3.org/1999/02/22-rdf-syntax-ns#object http://purl.obolibrary.org/obo/DOID_9352 http://purl.org/np/RAEYDBJplKT7agOpTcNYIHtwVLOaY__E2niBhZUqcU9mM#association http://www.w3.org/1999/02/22-rdf-syntax-ns#predicate https://w3id.org/biolink/vocab/treats http://purl.org/np/RAEYDBJplKT7agOpTcNYIHtwVLOaY__E2niBhZUqcU9mM#association http://www.w3.org/1999/02/22-rdf-syntax-ns#subject https://identifiers.org/drugbank:DB08907 http://purl.org/np/RAEYDBJplKT7agOpTcNYIHtwVLOaY__E2niBhZUqcU9mM#association http://www.w3.org/1999/02/22-rdf-syntax-ns#type http://www.w3.org/1999/02/22-rdf-syntax-ns#Statement http://purl.org/np/RAEYDBJplKT7agOpTcNYIHtwVLOaY__E2niBhZUqcU9mM#association http://www.w3.org/2000/01/rdf-schema#label invokana r as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus to reduce the risk of major adverse cardiovascular events cardiovascular death nonfatal myocardial infarction and nonfatal stroke in adults with type 2 diabetes mellitus and established cardiovascular disease cvd invokana is a sodium glucose co transporter 2 sglt2 inhibitor indicated as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus 1 to reduce the risk of major adverse cardiovascular events in adults with type 2 diabetes mellitus and established cardiovascular disease 1 limitations of use not for treatment of type 1 diabetes mellitus or diabetic ketoacidosis 1 limitations of use invokana is not recommended in patients with type 1 diabetes mellitus or for the treatment of diabetic ketoacidosis http://purl.org/np/RAEYDBJplKT7agOpTcNYIHtwVLOaY__E2niBhZUqcU9mM#association https://w3id.org/biolink/vocab/association_type https://w3id.org/biolink/vocab/ChemicalToDiseaseOrPhenotypicFeatureAssociation http://purl.org/np/RAEYDBJplKT7agOpTcNYIHtwVLOaY__E2niBhZUqcU9mM#association https://w3id.org/biolink/vocab/provided_by https://w3id.org/um/NeuroDKG http://purl.org/np/RAEYDBJplKT7agOpTcNYIHtwVLOaY__E2niBhZUqcU9mM#association https://w3id.org/biolink/vocab/relation https://schema.org/TreatmentIndication https://identifiers.org/drugbank:DB08907 https://w3id.org/biolink/vocab/category https://w3id.org/biolink/vocab/Drug http://purl.org/np/RAEYDBJplKT7agOpTcNYIHtwVLOaY__E2niBhZUqcU9mM#provenance http://purl.org/np/RAEYDBJplKT7agOpTcNYIHtwVLOaY__E2niBhZUqcU9mM#assertion http://www.w3.org/ns/prov#wasAttributedTo https://orcid.org/0000-0002-1468-3557 http://purl.org/np/RAEYDBJplKT7agOpTcNYIHtwVLOaY__E2niBhZUqcU9mM#pubinfo http://purl.org/np/RAEYDBJplKT7agOpTcNYIHtwVLOaY__E2niBhZUqcU9mM#sig http://purl.org/nanopub/x/hasAlgorithm RSA http://purl.org/np/RAEYDBJplKT7agOpTcNYIHtwVLOaY__E2niBhZUqcU9mM#sig http://purl.org/nanopub/x/hasPublicKey MIGfMA0GCSqGSIb3DQEBAQUAA4GNADCBiQKBgQCODwZkXojpEKwk7Ldj2oPPfCstvqrcpgCaTLo235K7ht9C7E1GCkLvUuL2b4VWXJTcZx/hxgDauR8hUeYq/lS6tfTL9yFZsnfl+PWYDyz7vv6N+wJVx2LL8bO6ntCjcOzvW2t2WUeF12Sb6b3I6uOYP0N8iQKts1WasY/yEYKAHQIDAQAB http://purl.org/np/RAEYDBJplKT7agOpTcNYIHtwVLOaY__E2niBhZUqcU9mM#sig http://purl.org/nanopub/x/hasSignature jCpcdTRGxE5e81fArhExhvhEVZdZh3d4XKSf2m8NpkPgflhhL0j5IAQyY/96RwmEKiFvjoYUFzymoXfzxf+A70mS8AgmttfkkW5Hen7jFviL/hOGX6CL4ZzHL536LcnpnxEkoV/ynrFFL6XFEDf9sWNCMh7ip1RUvFod+zvjSKA= http://purl.org/np/RAEYDBJplKT7agOpTcNYIHtwVLOaY__E2niBhZUqcU9mM#sig http://purl.org/nanopub/x/hasSignatureTarget http://purl.org/np/RAEYDBJplKT7agOpTcNYIHtwVLOaY__E2niBhZUqcU9mM http://purl.org/np/RAEYDBJplKT7agOpTcNYIHtwVLOaY__E2niBhZUqcU9mM http://purl.org/dc/terms/created 2021-06-12T14:45:11.988+02:00 http://purl.org/np/RAEYDBJplKT7agOpTcNYIHtwVLOaY__E2niBhZUqcU9mM http://purl.org/dc/terms/creator https://orcid.org/0000-0002-1468-3557 http://purl.org/np/RAEYDBJplKT7agOpTcNYIHtwVLOaY__E2niBhZUqcU9mM https://w3id.org/np/o/ntemplate/wasCreatedFromProvenanceTemplate http://purl.org/np/RANwQa4ICWS5SOjw7gp99nBpXBasapwtZF1fIM3H2gYTM http://purl.org/np/RAEYDBJplKT7agOpTcNYIHtwVLOaY__E2niBhZUqcU9mM https://w3id.org/np/o/ntemplate/wasCreatedFromPubinfoTemplate http://purl.org/np/RAA2MfqdBCzmz9yVWjKLXNbyfBNcwsMmOqcNUxkk1maIM http://purl.org/np/RAEYDBJplKT7agOpTcNYIHtwVLOaY__E2niBhZUqcU9mM https://w3id.org/np/o/ntemplate/wasCreatedFromTemplate http://purl.org/np/RAManV5GZI01JKzW_IPcfOXoiFTcZMmsV7qTCLkdzr4Gs